Epigenomics AG (EPGNF)
USD 0.79
(0.0%)
USD 0.79
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 9.78 Million EUR | 206.41% |
| 2022 | -9.19 Million EUR | 59.14% |
| 2021 | -22.5 Million EUR | -703.1% |
| 2020 | -2.8 Million EUR | 69.68% |
| 2019 | -9.24 Million EUR | 43.86% |
| 2018 | -16.46 Million EUR | -161.73% |
| 2017 | -6.29 Million EUR | 45.45% |
| 2016 | -11.53 Million EUR | -71.87% |
| 2015 | -6.7 Million EUR | -40.09% |
| 2014 | -4.78 Million EUR | 9.21% |
| 2013 | -5.27 Million EUR | -139.23% |
| 2012 | -2.2 Million EUR | 82.44% |
| 2011 | -12.55 Million EUR | 48.84% |
| 2010 | -24.54 Million EUR | -526.63% |
| 2009 | -3.91 Million EUR | 59.82% |
| 2008 | -9.74 Million EUR | -46.67% |
| 2007 | -6.64 Million EUR | 47.11% |
| 2006 | -12.56 Million EUR | 46.56% |
| 2005 | -23.51 Million EUR | 26.8% |
| 2004 | -32.12 Million EUR | -74.55% |
| 2003 | -18.4 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | -3.22 Million EUR | 49.94% |
| 2023 Q1 | -6.44 Million EUR | 29.87% |
| 2023 Q3 | 9.78 Million EUR | 403.11% |
| 2023 FY | 9.78 Million EUR | 206.41% |
| 2023 Q4 | 9.78 Million EUR | 0.0% |
| 2022 Q2 | -17.03 Million EUR | 10.42% |
| 2022 Q3 | -14.8 Million EUR | 13.09% |
| 2022 Q4 | -9.19 Million EUR | 37.9% |
| 2022 FY | -9.19 Million EUR | 59.14% |
| 2022 Q1 | -19.01 Million EUR | 15.48% |
| 2021 FY | -22.5 Million EUR | -703.1% |
| 2021 Q4 | -22.5 Million EUR | 2.31% |
| 2021 Q2 | -6.37 Million EUR | 6.46% |
| 2021 Q3 | -23.03 Million EUR | -261.5% |
| 2021 Q1 | -6.81 Million EUR | -143.11% |
| 2020 Q2 | -6.91 Million EUR | 26.32% |
| 2020 Q1 | -9.38 Million EUR | -1.55% |
| 2020 Q4 | -2.8 Million EUR | 43.86% |
| 2020 FY | -2.8 Million EUR | 69.68% |
| 2020 Q3 | -4.99 Million EUR | 27.82% |
| 2019 Q3 | -4.52 Million EUR | 39.04% |
| 2019 FY | -9.24 Million EUR | 43.86% |
| 2019 Q2 | -7.42 Million EUR | 35.17% |
| 2019 Q1 | -11.45 Million EUR | 30.4% |
| 2019 Q4 | -9.24 Million EUR | -104.11% |
| 2018 FY | -16.46 Million EUR | -161.73% |
| 2018 Q4 | -16.46 Million EUR | -1559.49% |
| 2018 Q2 | -1.76 Million EUR | 51.57% |
| 2018 Q1 | -3.64 Million EUR | 42.1% |
| 2018 Q3 | 1.12 Million EUR | 163.95% |
| 2017 FY | -6.29 Million EUR | 45.45% |
| 2017 Q4 | -6.29 Million EUR | 34.35% |
| 2017 Q3 | -9.58 Million EUR | -40.86% |
| 2017 Q2 | -6.8 Million EUR | 31.06% |
| 2017 Q1 | -9.86 Million EUR | 14.43% |
| 2016 Q2 | -11.94 Million EUR | -77.1% |
| 2016 Q4 | -11.53 Million EUR | -90.47% |
| 2016 FY | -11.53 Million EUR | -71.87% |
| 2016 Q1 | -6.74 Million EUR | -0.55% |
| 2016 Q3 | -6.05 Million EUR | 49.33% |
| 2015 Q1 | -3.75 Million EUR | 21.55% |
| 2015 FY | -6.7 Million EUR | -40.09% |
| 2015 Q2 | -8.38 Million EUR | -123.1% |
| 2015 Q4 | -6.7 Million EUR | 13.82% |
| 2015 Q3 | -7.78 Million EUR | 7.12% |
| 2014 Q4 | -4.78 Million EUR | -438.09% |
| 2014 Q2 | -3.75 Million EUR | 33.33% |
| 2014 FY | -4.78 Million EUR | 9.21% |
| 2014 Q1 | -5.62 Million EUR | -6.71% |
| 2014 Q3 | -890 Thousand EUR | 76.29% |
| 2013 Q3 | -1.67 Million EUR | 43.81% |
| 2013 Q4 | -5.27 Million EUR | -214.74% |
| 2013 FY | -5.27 Million EUR | -139.23% |
| 2013 Q2 | -2.98 Million EUR | 40.32% |
| 2013 Q1 | -4.99 Million EUR | -126.67% |
| 2012 Q3 | -5.68 Million EUR | 25.27% |
| 2012 FY | -2.2 Million EUR | 82.44% |
| 2012 Q4 | -2.2 Million EUR | 61.2% |
| 2012 Q2 | -7.6 Million EUR | 23.77% |
| 2012 Q1 | -9.97 Million EUR | 20.55% |
| 2011 Q1 | -21.52 Million EUR | 12.3% |
| 2011 Q2 | -18.72 Million EUR | 13.03% |
| 2011 Q3 | -15.65 Million EUR | 16.38% |
| 2011 Q4 | -12.55 Million EUR | 19.79% |
| 2011 FY | -12.55 Million EUR | 48.84% |
| 2010 Q4 | -24.54 Million EUR | 11.27% |
| 2010 FY | -24.54 Million EUR | -526.63% |
| 2010 Q1 | -16.46 Million EUR | -320.37% |
| 2010 Q2 | -30.49 Million EUR | -85.22% |
| 2010 Q3 | -27.66 Million EUR | 9.29% |
| 2009 Q4 | -3.91 Million EUR | 0.0% |
| 2009 FY | -3.91 Million EUR | 59.82% |
| 2008 FY | -9.74 Million EUR | -46.67% |
| 2007 FY | -6.64 Million EUR | 47.11% |
| 2006 FY | -12.56 Million EUR | 46.56% |
| 2005 FY | -23.51 Million EUR | 26.8% |
| 2004 FY | -32.12 Million EUR | -74.55% |
| 2003 FY | -18.4 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | -343.543% |
| Arrayit Corporation | 1.05 Million USD | -826.936% |
| Atlantic International Corp. | 236.49 Thousand USD | -4037.3% |
| Biocept, Inc. | -788 Thousand USD | 1341.694% |
| Bioqual, Inc. | -12 Million USD | 181.49% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | -42929.812% |
| DermTech, Inc. | 17.65 Million USD | 44.573% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 101.709% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | 232.638% |
| iMD Companies, Inc. | 1.11 Million USD | -776.819% |
| IDenta Corp. | 524.85 Thousand USD | -1764.249% |
| Interpace Biosciences, Inc. | 7.69 Million USD | -27.171% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | 36403.61% |
| InVitro International | -313.14 Thousand USD | 3224.636% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | -524.846% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | 1372407.013% |
| Medical Imaging Corp. | 3.79 Million USD | -158.104% |
| NovelStem International Corp. | 3.52 Million USD | -177.849% |
| Optigenex Inc. | 8.93 Million USD | -9.521% |
| PharmChem, Inc. | -1.49 Million USD | 754.742% |
| Proteome Sciences plc | 14.57 Million USD | 32.86% |
| Response Genetics, Inc | -13.08 Million USD | 174.771% |
| Rennova Health, Inc. | 14.82 Million USD | 34.021% |
| RushNet, Inc. | 4.8 Million USD | -103.809% |
| ScreenPro Security Inc. | 135.58 Thousand USD | -7116.329% |
| Stella Diagnostics Inc. | 6.19 Million USD | -57.992% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | -448.339% |
| Todos Medical Ltd. | 38.31 Million USD | 74.462% |